Zobrazeno 31 - 40
of 42
pro vyhledávání: '"Shannon R. Morris"'
Autor:
Lisa A. Carey, Shannon R. Morris
Publikováno v:
Reviews in endocrinemetabolic disorders. 8(3)
Molecular profiling has provided biological evidence for the heterogeneity of breast cancer through the identification of intrinsic subtypes like Luminal A, Luminal B, HER2+/ER− and basal-like. It has also led to the development of clinically appli
Autor:
Shannon R, Morris, Lisa A, Carey
Publikováno v:
Oncology (Williston Park, N.Y.). 20(14)
Up to 25% of patients diagnosed with breast cancer have tumors that overexpress HER2. HER2-positive breast cancer is highly proliferative, difficult to treat, and confers a poor prognosis. The advent of the anti-HER2 monoclonal antibody trastuzumab (
Autor:
Marcia Hall, M. Buck, Shannon R. Morris, T. Meniawy, D.A. Smith, Linda Mileshkin, D. McAleer, Anne Hamilton, S. Anandra, Shirley Wong, Hani Gabra, B.A. Reedy, R.B. Noble, Sarah P. Blagden
Publikováno v:
European Journal of Cancer. 50:7
Autor:
Azeem Saleem, Sarah P. Blagden, Hani Gabra, Euan A. Stronach, S. A. Babar, Shannon R. Morris, Gordon B. Mills, Edward Curry, Roshan Agarwal, H. Gunqor
Publikováno v:
European Journal of Cancer. 47:12-13
Evaluation Of Afuresertib, An Oral Pan-AKT Inhibitor, In Patients With Langerhans Cell Histiocytosis
Autor:
Beth Ann Reedy, Alison Portnoy, Mark L. Heaney, Robert Vassallo, Allen Oliff, Eric D. Jacobsen, Carlos Rodriguez-Galindo, Shannon R. Morris, Stephen Szabo, Ivan Borrello, Kenneth L. McClain, Ira J. Dunkel, James A. Whitlock, Deborah A. Smith, Robert J. Arceci, Sarah Vaseilbuh, Amy A. Murnane, Carl E. Allen, Bob Noble
Publikováno v:
Blood. 122:2907-2907
Background Langerhans cell histiocytosis (LCH) is a heterogeneous disease whose myriad manifestations result from accumulation of Langerhans cells in a variety of organs most commonly including skin, bone, central nervous system, liver, lymph nodes,
Autor:
Simon J. Harrison, Joanna Opalinska, Deborah A. Smith, Richard A. Brigandi, Steven J. Freedman, Shannon R. Morris, Sung-Soo Yoon, Allen Oliff, Andrew Spencer, Christine Chen
Publikováno v:
Blood. 118:1856-1856
Abstract 1856 Background: Despite significant progress in treatment, multiple myeloma (MM) remains an incurable disease. There is a well recognized need for new agents with novel mechanisms of action, which would complement currently available drugs.
Autor:
Thomas A. Lampkin, J.H.M. Schellens, Adil Daud, Elizabeth Claire Dees, Jennifer M. Specht, E. Y. Yu, E. E. Voest, Gerald Steven Falchook, Martijn P. Lolkema, Emily K. Bergsland, Shannon R. Morris, R. Kurzrock, Deborah A. Smith, Juneko E. Grilley-Olson, Sheng-Bin Peng, Siquing Fu, Joseph F. Kleha, Antoinette R. Tan, Pamela N. Munster, R. van der Noll
Publikováno v:
Journal of Clinical Oncology. 29:3018-3018
3018 Background: Phosphatidylinositol 3-kinase (PI3K) is critical to cancer cell growth, survival, and metabolism. GSK458 is an oral, potent inhibitor of PI3K (α, β, γ, δ), mTORC1, and mTORC2. Preclinically, GSK458 has demonstrated broad anti-tum
Autor:
Donna S. Cox, T. Gonzalez, Theresa Mays, Amita Patnaik, David S. Hong, R. Kurzrock, Deborah A. Smith, Glenda Chambers, Apostolia-Maria Tsimberidou, L. Rosenstein, J. L. Gauvin, Anthony W. Tolcher, Lon Smith, Douglas J Demarini, Kyri Papadopoulos, Siquing Fu, Shannon R. Morris, Ngocdiep Le, Aung Naing, Gerald Steven Falchook
Publikováno v:
Journal of Clinical Oncology. 29:3085-3085
3085 Background: The RAS/RAF/MEK and PI3K/AKT pathways are activated in many human cancers. GSK212 is a potent and selective allosteric inhibitor of MEK1/2 and GSK795 is a potent ATP-competitive in...
Autor:
A. Santiago-Walker, Azeem Saleem, Emily Pickford, Sarah P. Blagden, Roger N. Gunn, Yvonne Lewis, E. Krachey, Roshan Agarwal, Hani Gabra, M. Chen, S. C. Carme, Hatice Gungor, Deborah A. Smith, Mona El-Bahrawy, Euan A. Stronach, S. A. Babar, Shannon R. Morris, Nona Rama, Cristian Salinas, Agnieszka Michael
Publikováno v:
Journal of Clinical Oncology. 29:5064-5064
5064 Background: GSK795 is a potent, ATP-competitive, pan AKT inhibitor. The purpose of this study was to characterize the relationship between AKT inhibition by GSK795 and downstream effects in platinum resistant ovarian cancer pts. Methods: Pts wit
Autor:
Wells A. Messersmith, P. G. Kaminker, H. A. Burris, Branimir I. Sikic, Shannon R. Morris, D.R. Camidge, Hua Li, Heather A. Wakelee, J. R. Infante, G. Gallant, S. G. Eckhardt, A.D. Colevas, Suzanne F. Jones
Publikováno v:
Journal of Clinical Oncology. 29:3008-3008
3008 Background: IAPs are key regulators of cancer cell survival, which makes them appealing targets for cancer therapy. HGS1029 is a small molecule IAP inhibitor which directly kills tumor cells as a single-agent or in combination. Methods: The safe